Advancing Oncology: TransCure bioServices Showcases Innovations at 3rd Global Cancer Consortium Conference
TransCure bioServices is proud to actively participate in the 3rd International Global Cancer Consortium (GCC) Conference, organized in collaboration with the GCC South Asia Chapter and the Advanced Centre for Treatment, Research, and Education in Cancer (ACTREC). The event, focusing on current trends in the tumor microenvironment and associated therapies, will take place on February 3rd and 4th, 2024, with a demonstration workshop on “Humanized Mice: Model Generation and Applications to Anti-Cancer Immunotherapeutic Drug Development” scheduled for February 5th, 2024.
- Extracellular Matrix Interactions
- Cancer Fibroblasts and Signaling
- Humanized Mice and Applications in Immunotherapy Drug Development
The audience will encompass scientists, clinicians, graduate students, and postdoctoral fellows from both the academic and industrial sectors, uniting participants from India as well as various institutions in the United States, Asia, Europe, and Africa. Esteemed speakers hailing from India, the United States and Europe have received invitations to share their expertise and insights. The presentations by these international experts, along with discussions on the latest developments in the tumor microenvironment, aim to cultivate collaboration in scientific research and education — a pivotal objective of this conference.
A demonstration workshop on “Humanized Mice Generation and Applications” will provide participants with in-depth knowledge of experimental details, data analysis, and interpretation in immunomodulatory drug testing (CAR-T or immune checkpoint inhibitors/herbal-based) using cutting-edge models.
Our General Director, Sébastien Tabruyn, PhD, will have the honor of presenting TransCure Bioservices’ preclinical services and advanced human immune system mouse models for the study of cancer treatments. His presentation will highlight our expertise in preclinical research and our commitment to scientific progress.
Presentation during the event by:
Sebastien Tabruyn, PhD, General Director
Sebastien Tabruyn holds a PhD in Molecular Biology from the University of Liege (Belgium). With over 20 years of experience as a Project Leader in worldwide academic research institutes, including UCSF (California, USA), the Centre for Cancer Biology (Adelaide, Australia), and the University of Maastricht (Netherlands), Sebastien joined TransCure bioServices in 2013 to develop the first immune-oncology humanized mouse models. Before taking on the role of General Director, Sebastien served as the company’s Chief Scientific Officer for six years, where he was instrumental in driving scientific excellence and innovation. Sebastien Tabruyn has published more than 35 peer-reviewed publications, primarily focusing on oncology, inflammation, immunity, and angiogenesis. As General Director, Sebastien commits his leadership and vision to the expansion of TransCure bioServices through the successful delivery of its client needs.